Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Marla C. Dubinsky et al.|The Lancet|2022Cited by 383
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Geert D’Haens, Remo Panaccione et al.|The Lancet|2022Cited by 312
[Disseminated Penicillium marneffei infection associated with AIDS, report of a case].Xiaomei Liao, Weiping Liu, Huijiao Chen et al.|PubMed|2002Cited by 8